...
首页> 外文期刊>Chemico-biological interactions >The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.
【24h】

The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.

机译:新型铜络合物在克服Ehrlich腹水癌细胞对阿霉素的耐药性中的作用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

One of the important pathways of resistance to anthracyclines is governed by elevated levels of glutathione (GSH) in cancer cells. Resistant cells having elevated levels of GSH show higher expression of multidrug-resistant protein (MRP); the activity of glutathione S-transferases (GSTs) group of enzymes have also been found to be higher in some drug-resistant cells. The general mechanism in this type of resistance seems to be the formation of conjugates enzymatically by GSTs, and subsequent efflux by active transport through MRP (MRP1-MRP9). MRPs act as drug efflux pump and can also co-transport drugs like doxorubicin (Dox) with GSH. Depletion of GSH in resistant neoplastic cells may possibly sensitize such cells, and thus overcome multidrug resistance (MDR). A number of resistance modifying agents (RMA) like DL-buthionine (S, R) sulfoxamine (BSO) and ethacrynic acid (EA) moderately modulate resistance by acting as a GSH-depleting agent. As most of the GSH-depleting agents have dose-related toxicity, development of non-toxic GSH-depleting agent has immense importance in overcoming MDR. The present study describes the resistance reversal potentiality of novel copper complex, viz., copper N-(2-hydroxy acetophenone) glycinate (CuNG) developed by us in Dox-resistant Ehrlich ascites carcinoma (EAC/Dox) cells. CuNG depletes GSH in resistant (EAC/Dox) cells possibly by forming conjugate with it. Depletion of GSH results in higher Dox accumulation that may lead to enhanced rate of apoptosis in EAC/Dox cells. In vivo studies with male Swiss albino mice bearing ascitic growth of EAC/Dox showed tremendous increase in life span (treated/control, T/C = 453%) for the treated group with apparent regression of tumor. Resistance to Dox in EAC/Dox cells is associated with over expression of GST-P1, GST-M1 (enzymes involved in phase II detoxification) and MRP1 (a transmembrane ATPase efflux pump for monoglutathionyl conjugates of xenobiotics). CuNG causes down regulation of all these three proteins in EAC/Dox cells. The effect of CuNG as RMA is better than BSO in many aspects.
机译:抗蒽环类药物的重要途径之一是癌细胞中谷胱甘肽(GSH)含量的升高。具有高水平GSH的抗性细胞表现出较高的耐多药蛋白(MRP)表达;谷胱甘肽S-转移酶(GSTs)的酶活性在某些耐药细胞中也被发现更高。这种抗药性的一般机制似乎是由GST酶促形成结合物,以及随后通过MRP(MRP1-MRP9)的主动转运而流出。 MRP充当药物外排泵,也可以与GSH共同运输阿霉素(Dox)等药物。耐药性赘生性细胞中GSH的耗竭可能会使此类细胞敏感,从而克服多药耐药性(MDR)。多种抗性改性剂(RMA),例如DL-丁硫氨酸(S,R)磺胺(BSO)和乙炔酸(EA)通过充当GSH消耗剂来适度调节抗性。由于大多数的GSH消耗剂具有剂量相关的毒性,因此开发无毒的GSH消耗剂对克服MDR极为重要。本研究描述了我们开发的新型铜络合物,即N-(2-羟基苯乙酮)甘氨酸铜(CuNG)在耐Dox的埃氏腹水癌(EAC / Dox)细胞中的耐药逆转潜力。 CuNG可能通过与抗性(EAC / Dox)细胞形成偶联物来耗尽GSH。 GSH的消耗导致更高的Dox积累,这可能导致EAC / Dox细胞凋亡的速率增加。对带有EAC / Dox腹水生长的雄性瑞士白化病小鼠的体内研究显示,治疗组的寿命显着增加(治疗/对照,T / C = 453%),且肿瘤明显消退。 EAC / Dox细胞对Dox的抗性与GST-P1,GST-M1(参与II期排毒的酶)和MRP1(用于异源生物的单谷胱甘肽结合物的跨膜ATPase外排泵)的过表达有关。 CuNG导致EAC / Dox细胞中所有这三种蛋白质的下调。 CuNG作为RMA的效果在许多方面都优于BSO。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号